Item 16. FORM 10-K SUMMARY

5K characters. Original on sec.gov · Markdown

Item 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Abbott Laboratories has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	ABBOTT LABORATORIES


	By	/s/ ROBERT B. FORD
		Robert B. Ford President and Chief Executive Officer

	Date:	February 19, 2021

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of Abbott Laboratories on February 19, 2021 in the capacities indicated below.

/s/ ROBERT B. FORD		/s/ ROBERT E. FUNCK, JR.
Robert B. Ford		Robert E. Funck, Jr.
President and Chief Executive Officer, and Director of Abbott Laboratories (principal executive officer)		Executive Vice President, Finance and Chief Financial Officer (principal financial officer)


/s/ PHILIP P. BOUDREAU		/s/ MILES D. WHITE
Philip P. Boudreau		Miles D. White
Vice President, Finance and Controller (principal accounting officer)		Executive Chairman of the Board


/s/ ROBERT J. ALPERN		/s/ ROXANNE S. AUSTIN
Robert J. Alpern, M.D.		Roxanne S. Austin
Director of Abbott Laboratories		Director of Abbott Laboratories


/s/ SALLY E. BLOUNT		/s/ MICHELLE A. KUMBIER
Sally E. Blount, Ph.D.		Michelle A. Kumbier
Director of Abbott Laboratories		Director of Abbott Laboratories


/s/ EDWARD M. LIDDY		/s/ DARREN W. MCDEW
Edward M. Liddy Director of Abbott Laboratories		Darren W. McDew Director of Abbott Laboratories


/s/ NANCY MCKINSTRY		/s/ PHEBE N. NOVAKOVIC
Nancy McKinstry		Phebe N. Novakovic
Director of Abbott Laboratories		Director of Abbott Laboratories


/s/ WILLIAM A. OSBORN		/s/ DANIEL J. STARKS
William A. Osborn		Daniel J. Starks
Director of Abbott Laboratories		Director of Abbott Laboratories


/s/ JOHN G. STRATTON		/s/ GLENN F. TILTON
John G. Stratton		Glenn F. Tilton
Director of Abbott Laboratories		Director of Abbott Laboratories

ABBOTT LABORATORIES AND SUBSIDIARIES

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS

FOR THE YEARS ENDED DECEMBER 31, 2020, 2019 AND 2018

(in millions of dollars)


					Amounts
	Balance		Provisions/		Charged Off
Allowances for Doubtful	at Beginning		Charges		and Other		Balance at
Accounts and Product Returns	of Year		to Income		Deductions		End of Year
2020	$	384	$	187	$	(111)	$	460
2019		314		137		(68)		384
2018		294		110		(90)		314

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of Abbott Laboratories

Opinion on the Financial Statement Schedule

We have audited the consolidated financial statements of Abbott Laboratories and subsidiaries (the Company) as of December 31, 2020 and 2019, for each of the three years in the period ended December 31, 2020, and have issued our report thereon dated February 19, 2021 (included elsewhere in this Annual Report on Form 10-K). Our audits of the consolidated financial statements included the financial statement schedule listed in Item 15(a)(2) of this Annual Report on Form 10-K (the “schedule”). This schedule is the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s schedule, based on our audits.

In our opinion, the schedule presents fairly, in all material respects, the information set forth therein when considered in conjunction with the consolidated financial statements.

/s/ Ernst & Young LLP

Chicago, Illinois

February 19, 2021

Previous: Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES